Latest Polyneuropathy Stories
Up to 92 percent reduction in transthyretin protein in patients with familial amyloid polyneuropathy CARLSBAD, Calif., April 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
NARBERTH, Pa., Nov.
- LUNAR-101, an UNA(TM) oligomer therapeutic for transthyretin-mediated familial amyloid cardiomyopathy (TTR-FAC), exhibited in non-human primates TTR reduction greater than 90% with a single low dose
- Greater than 100-fold Allele-specific silencing of V30M variant for the treatment of Familial Amyloid Polyneuropathy (TTR-FAP) - SAN DIEGO, May 13, 2014 /PRNewswire/ --
- LUNAR TM technology for the delivery of RNA medicines to multiple target organs and tumors will be presented SAN DIEGO, March 27, 2014 /PRNewswire/ --
AlignLife provides a free webinar to educate on Cholesterol and the risk of statin medications. (PRWEB) February 19, 2014 This Thursday, February 20th
On Monday, August 12, 2013, neuropathy patients and their loved ones joined The Neuropathy Association to visit the New York Stock Exchange and ring the Closing Bell to raise awareness of the
“Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease”
- an ornament or knob in the shape of a flower